An Automated Micro Solid-Phase Extraction (μSPE) Liquid Chromatography-Mass Spectrometry Method for Cyclophosphamide and Iphosphamide: Biological Monitoring in Antineoplastic Drug (AD) Occupational Exposure

Author:

Dugheri Stefano1ORCID,Squillaci Donato1ORCID,Saccomando Valentina1,Marrubini Giorgio2ORCID,Bucaletti Elisabetta1ORCID,Rapi Ilaria1,Fanfani Niccolò1,Cappelli Giovanni1,Mucci Nicola1ORCID

Affiliation:

1. Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy

2. Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy

Abstract

Despite the considerable steps taken in the last decade in the context of antineoplastic drug (AD) handling procedures, their mutagenic effect still poses a threat to healthcare personnel actively involved in compounding and administration units. Biological monitoring procedures usually require large volumes of sample and extraction solvents, or do not provide adequate sensitivity. It is here proposed a fast and automated method to evaluate the urinary levels of cyclophosphamide and iphosphamide, composed of a miniaturized solid phase extraction (µSPE) followed by ultrahigh-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) analysis. The extraction procedure, developed through design of experiments (DoE) on the ePrep One Workstation, required a total time of 9.5 min per sample, with recoveries of 77–79% and a solvent consumption lower than 1.5 mL per 1 mL of urine sample. Thanks to the UHPLC-MS/MS method, the limits of quantification (LOQ) obtained were lower than 10 pg/mL. The analytical procedure was successfully applied to 23 urine samples from compounding wards of four Italian hospitals, which resulted in contaminations between 27 and 182 pg/mL.

Publisher

MDPI AG

Reference38 articles.

1. (2023, November 07). Global Anticancer Drugs Market to Record 6.7% CAGR through 2027. Available online: https://www.biospace.com/article/global-anticancer-drugs-market-to-record-6-7-percent-cagr-through-2027/.

2. (2023, April 19). EUR-Lex-32022L0431-EN-EUR-Lex. Available online: https://eur-lex.europa.eu/eli/dir/2022/431.

3. (2023, March 20). Amendments to the Carcinogens and Mutagens Directive on Hazardous Drugs and Implications for Change to the Healthcare System in Europe to Ensure Compliance with Its Requirements. Available online: https://www.europeanbiosafetynetwork.eu/wp-content/uploads/2019/03/Amendments-to-CMD3-and-implications.pdf.

4. (2023, June 11). Directive (EU) 2019/983 of the European Parliament and of the Council of 5 June 2019 Amending Directive 2004/37/EC on the Protection of Workers from the Risks Related to Exposure to Carcinogens or Mutagens at Work. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32019L0983.

5. (2023, March 23). Protecting Health Workers from Hazardous Products. Available online: https://www.europeanbiosafetynetwork.eu/protecting-health-workers-from-hazardous-products/.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3